FINWIRES · TerminalLIVE
FINWIRES

HKG:0719

5 stories mentioning HKG:0719Updated 29d ago

Every FINWIRES story that references HKG:0719, newest first.

Asia

Xinhua Pharma's Anxiety Drug Passes Chinese Regulator's Quality Consistency Evaluation; Secures Approval

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained approval for the supplementary drug application for its phenobarbital tablets from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval came as the drug passed the regulator's consistency of quality and efficacy evaluation.Phenobarbital tablets are mainly used to treat anxiety, insomnia, epilepsy, and grand mal and partial seizures.

HKG:0719SHE:000756
Asia

Xinhua Pharma Gets China Approval for Respiratory Drug

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained drug registration from China's drug regulator for ambroxol hydrochloride and clenbuterol hydrochloride oral solution.The drug treats cough, viscous sputum, expectoration difficulty and wheezing from bronchitis, emphysema and other respiratory diseases, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 3% on the Shenzhen bourse and 1% on the Hong Kong bourse.

HKG:0719SHE:000756
Asia

Xinhua Pharmaceutical Gets China Nod to Market Parkinson's Drug

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained approval to market Benserazide Hydrochloride from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.Benserazide hydrochloride tablets, combined with Levodopa, are used to treat Parkinson's disease and symptomatic Parkinsonism.

HKG:0719SHE:000756
Asia

Xinhua Pharmaceutical's Q1 Profit Slides 25%

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) recorded a 25% decline in attributable profit in the first quarter of 2026 to 83.9 million yuan from 112.1 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Earnings per share slipped to 0.12 yuan from 0.15 yuan in the corresponding period of the previous fiscal year.The pharma firm's operating income slipped 0.3% to 2.42 billion yuan from 2.43 billion yuan in the year-ago period.

HKG:0719SHE:000756
Asia

Shandong Xinhua Pharma Gets China Nod to Register Bumetanide Injection

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its drug registration application for Bumetanide injection was approved by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug is indicated for conditions including edema related to heart, liver, and kidney diseases, as well as hypertension and acute renal failure, the filing said.

HKG:0719SHE:000756

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:0719 in your portfolio
WheelAI
WheelAI
Analyze HKG:0719 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:0719